Skip to content
Linkedin
RLS logo_header
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
Linkedin

FORE Biotherapeutics Raises $38 Million in Series D-2 Financing for the Continued Advancement of Plixorafenib

May 27, 2025

Orionis Biosciences and Genentech to Discover and Develop Molecular Glue Class Medicines for Cancer

May 27, 2025

OSE Immunotherapeutics, Inside Therapeutics, and Angers-based MiNT Laboratory to develop mRNA therapeutics and accelerate nanodrug development

May 27, 2025

Helix BioPharma Secures Pre-IND Candidates LEUMUNA™ and GEMCEDA™ in Strategic Acquisition from the Laevoroc Group

May 27, 2025

Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-022 In Combination with KEYTRUDA

May 21, 2025

Coherus BioSciences Focuses on Oncology After Divestitures

May 21, 2025

Tempus Enters Multi-Year Strategic Collaboration With Boehringer Ingelheim to Advance Its Cancer Pipeline

May 21, 2025

AbbVie and ADARx Pharmaceuticals to Develop Next-Gen siRNA Therapies Across Multiple Therapeutic Areas

May 21, 2025

AstraZeneca announced the successful completion of the acquisition of EsoBiotec

May 21, 2025

Aranscia Acquires Spesana to Advance Precision Oncology

May 21, 2025

Atossa Announced Strategic Decision to Pursue Metastatic Breast Cancer Indication for (Z)-endoxifen

May 21, 2025

Leap Therapeutics undergoes strategic restructuring to prioritize clinical development of sirexatamab in CRC resulting in an approximately 50% reduction in workforce

May 21, 2025

Tempus Enters Multi-Year Strategic Collaboration with Boehringer Ingelheim to Advance its Cancer Pipeline

May 21, 2025

Alpheus Medical Raises $52M in Series B Round to Advance Glioblastoma Therapy

May 21, 2025

Nearly 50 Sites Activated Across U.S. for Pivotal Ph 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in 1L Consolidation in LBCL

May 21, 2025

Regeneron Enters into Asset Purchase Agreement to Acquire 23andMe for $256M

May 21, 2025

Pfizer Enters into Exclusive Licensing Agreement with 3SBio

May 21, 2025

Cellipont Bioservices and Optieum Biotechnologies Partner to Advance cGMP Manufacturing of CAR-T Therapy for Glioblastoma

May 13, 2025

IND application submitted to the U.S. FDA for UTRxM1-18 for targeting c-MYC driven cancers

May 13, 2025

Sandoz enters global collaboration license agreement with Henlius to commercialize ipilimumab in multiple indications

May 6, 2025

Concentra Biosciences to Acquire Kronos Bio 

May 6, 2025

Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics

May 6, 2025

VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific ADC Program

May 6, 2025

Mosaic Therapeutics in-licenses two clinical-stage oncology programs from Astex Pharmaceuticals

April 30, 2025

Halozyme Sues Merck for Patent Infringement over SC Keytruda Formulation

April 30, 2025
Page1 Page2 Page3 … Page27

Onco-This-Week

  • Business News
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Conference Coverage

About Us

Sign up for OTW

Linkedin

Disclaimer: The OTW team takes care to share authentic information. In case of any discrepancies please write to newsletter@onco-this-week.com. Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is part of RLS Consultants, a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.